CoChat

Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia

Open access

The DOI matches its Crossref record; 34 of the 37 references it cites were found in a registry or an index.

Abstract

Entry into the cell cycle is mediated by cyclin-dependent kinase 4/6 (CDK4/6) activation, followed by CDK2 activation. We found that pharmacologic inhibition of the Flt3 internal tandem duplication (ITD), a mutated receptor tyrosine kinase commonly found in patients with acute myelogenous leukemia (AML), led to the down-regulation of cyclin D2 and D3 followed by retinoblastoma protein (pRb) dephosphorylation and G(1) cell-cycle arrest. This implicated the D-cyclin-CDK4/6 complex as a downstream effector of Flt3 ITD signaling. Indeed, single-agent PD0332991, a selective CDK4/6 inhibitor, caused sustained cell-cycle arrest in Flt3 ITD AML cell lines and prolonged survival in an in vivo model of Flt3 ITD AML. PD0332991 caused an initial cell-cycle arrest in well-established Flt3 wild-type (wt) AML cell lines, but this was overcome by down-regulation of p27(Kip) and reactivation of CDK2. This acquired resistance was not observed in a Flt3 ITD and a Flt3 wt sample from a patient with primary AML. In summary, the mechanism of cell-cycle arrest after treatment of Flt3 ITD AML with a Flt3 inhibitor involves down-regulation of cyclin D2 and D3. As such, CDK4/6 can be a therapeutic target in Flt3 ITD AML but also in primary Flt3 wt AML. Finally, acquired resistance to CDK4/6 inhibition can arise through activation CDK2.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2007-02-071266

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 34 references

Cited by

See all 140

Metadata

Authors
Wang, L., Wang, J., Blaser, B. W., Duchemin, A.-M., Kusewitt, D. F., Liu, T., Caligiuri, M. A., & Briesewitz, R.
Affiliations
  • Department of Pharmacology,
  • Department of Internal Medicine and the Integrated Biomedical Science Graduate Program,
  • Department of Psychiatry, and
  • Department of Veterinary Biosciences,
  • The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
Venue
Blood
Published
2007-09-15
Volume
110
Issue
6
Pages
2075-2083
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2057274133
Cited by
134
References
37
Citations by year
2026: 2 · 2025: 8 · 2024: 3 · 2023: 6 · 2022: 12 · 2021: 5 · 2020: 9 · 2019: 12 · 2018: 10 · 2017: 8 · 2016: 8 · 2015: 10 · 2014: 9 · 2013: 9 · 2012: 7
FWCI
2.14
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Pharmacology (medical) › Flavonoids in Medical Research
Keywords
CDK4/6 inhibition, acute myeloid leukemia, FLT3-ITD, palbociclib, cyclin D2, cyclin D3, retinoblastoma protein phosphorylation, G1 cell cycle arrest, p27, acquired drug resistance, CDK4/6 inhibitor resistance
MeSH terms
Acute Disease, Animals, Bone Marrow Cells, Humans, Indoles, Leukemia, Myeloid, Morpholines, Mutation, Phosphorylation, Piperazines, Pyridines, Pyrroles, Tumor Cells, Cultured, Blotting, Western, Signal Transduction, Retinoblastoma Protein, G1 Phase, Cyclins, Mice, SCID, Immunoprecipitation, Intracellular Signaling Peptides and Proteins, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p27, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, fms-Like Tyrosine Kinase 3, Cyclin D2, Cyclin D3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. https://app.cochat.ai/papers/10.1182/blood-2007-02-071266
The paper
Wang, L., Wang, J., Blaser, B. W., Duchemin, A.-M., Kusewitt, D. F., Liu, T., Caligiuri, M. A., & Briesewitz, R. (2007). Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood. https://doi.org/10.1182/blood-2007-02-071266

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.